TY - JOUR
T1 - Prostate cancer detection strategies
AU - Brand, Timothy C.
AU - Hernandez, Javier
AU - Canby-Hagino, Edith D.
AU - Basler, Joseph W.
AU - Thompson, Ian M
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2006/5
Y1 - 2006/5
N2 - Prostate cancer is the most common malignancy in men and, as a result, there has been a nationwide emphasis on screening and detection. With the widespread use of the prostate-specific antigen (PSA), prostate cancer screening effectively detects localized prostate cancer. However, recent reports have identified a significant proportion of prostate cancer in men with low PSA levels. Many of these cancers are higher-grade malignancies. Consequently, PSA may function more effectively as a screening tool when applied over a continuum that is associated with degree of risk, rather than a binary measure. Other markers are currently being investigated. Ideally, a marker will identify the malignancy that is a clinical threat, thereby avoiding intervention for indolent disease. Prevention strategies may be employed for higher-risk patients, and these strategies eventually may be tailored to genetic or other risks.
AB - Prostate cancer is the most common malignancy in men and, as a result, there has been a nationwide emphasis on screening and detection. With the widespread use of the prostate-specific antigen (PSA), prostate cancer screening effectively detects localized prostate cancer. However, recent reports have identified a significant proportion of prostate cancer in men with low PSA levels. Many of these cancers are higher-grade malignancies. Consequently, PSA may function more effectively as a screening tool when applied over a continuum that is associated with degree of risk, rather than a binary measure. Other markers are currently being investigated. Ideally, a marker will identify the malignancy that is a clinical threat, thereby avoiding intervention for indolent disease. Prevention strategies may be employed for higher-risk patients, and these strategies eventually may be tailored to genetic or other risks.
UR - http://www.scopus.com/inward/record.url?scp=33750377751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750377751&partnerID=8YFLogxK
U2 - 10.1007/s11934-006-0019-8
DO - 10.1007/s11934-006-0019-8
M3 - Review article
C2 - 16630521
AN - SCOPUS:33750377751
VL - 7
SP - 181
EP - 185
JO - Current Urology Reports
JF - Current Urology Reports
SN - 1527-2737
IS - 3
ER -